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Abstract
The concentration of glucose in plasma is held within narrow limits (4–10 mmol/l), primarily to ensure fuel supply to the brain.
Kidneys play a role in glucose homeostasis in the body by ensuring that glucose is not lost in the urine. Three membrane proteins
are responsible for glucose reabsorption from the glomerular filtrate in the proximal tubule: sodium−glucose cotransporters
SGLT1 and SGLT2, in the apical membrane, and GLUT2, a uniporter in the basolateral membrane. ‘Knockout’ of these
transporters in mice and men results in the excretion of filtered glucose in the urine. In humans, intravenous injection of the
plant glucoside phlorizin also results in excretion of the full filtered glucose load. This outcome and the finding that, in an animal
model, phlorizin reversed the symptoms of diabetes, has stimulated the development and successful introduction of SGLT2
inhibitors, gliflozins, in the treatment of type 2 diabetes mellitus. Here we summarise the current state of our knowledge about the
physiology of renal glucose handling and provide background to the development of SGLT2 inhibitors for type 2 diabetes
treatment.
Keywords Gliflozins . Glucose . GLUTs . Inhibitors . Kidney . Phlorizin . Proximal tubule . Review . SGLTs . Type 2 diabetes
mellitus
Abbreviations
2-FDG 2-Deoxy-2-fluoro-[18F]-D-glucose
F-Dapa 4-[18F]fluoro-dapagliflozin
HEK 293 Human embryonic kidney cells
Ki Inhibitor constant
Km Apparent affinity constant
Me-4FDG Methyl-4-fluoro-[18F]-4-deoxy-
D-glucopyranoside
OMIM Online Mendelian Inheritance in Man
PET Positron emission tomography
PKA Protein kinase A
PKC Protein kinase C
SGLT Sodium−glucose cotransporter
TM Transmembrane helix
Introduction
Although the kidneys freely filter plasma glucose, none ap-
pears in the urine. However, in diabetes, glucose may appear
in the urine, specifically when the plasma glucose concentra-
tion is so high that the filtered load exceeds the maximum
capacity for sugar reabsorption. Homer Smith and his col-
leagues were the first to quantify glomerular filtration rates
in humans. They showed that all the filtered glucose was nor-
mally reabsorbed and, importantly, they also demonstrated
that reabsorption of total filtered glucose load could be
inhibited by a compound called phlorizin (Fig. 1) [1]. This
prompted decades of research into the location and mecha-
nism of kidney glucose transport, mostly in animal models.
A brief history of the discovery of renal glucose transporters
Early micropuncture experiments on amphibians and rats
found that glucose was completely reabsorbed in the proximal
tubule (Fig. 2). Following the pioneering work of Mo Burg
who introduced techniques for research on isolated perfused
kidney tubules (reviewed in [2]), Barfuss and Schafer [3]
found that the capacity for glucose absorption was tenfold
larger in early (S2) rabbit proximal tubules than late (S3) tu-
bules. Furthermore, they found that the affinity for glucose
was higher in S3 tubules than S2 tubules, and that luminal
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phlorizin blocked absorption in both segments. This led to the
concept that the bulk of glucose reabsorption occurred in the
early proximal tubule (S1 and S2 segments), and that the later
segment (S3) ‘mopped up’ the rest.
Our understanding of the mechanism of sugar transport has
largely rested on the progress stemming from Bob Crane’s
1961 sodium–glucose cotransport hypothesis that glucose
transport across the intestinal brush border membrane is uphill
and coupled with the downhill movement of sodium. Stan
Schultz and Pete Curran largely confirmed and expanded
Crane’s hypothesis in the broader context of trans-epithelial
transport [4]. Ultimate experimental proof of cotransport came
from seminal work by Ulrich Hopfer and colleagues on iso-
lated brush border membrane vesicles [5]. For a summary of
the early history of the cotransport hypothesis, see [6]. The
second step of intestinal glucose absorption, passive exit from
the cell across the basolateral membrane, was thought to occur
by facilitated diffusion. This two-stepped process explains
how glucose absorption can occur against a concentration gra-
dient across the intestinal epithelium (see [4]).
An early analysis of two rare genetic disorders of intestinal
and renal glucose transport, familial renal glucosuria and glu-
cose–galactose malabsorption, led to the hypothesis that two
genes are primarily involved in glucose reabsorption in the
kidney, with one of these genes also being expressed in the
small intestine (giving rise to glucose–galactose malabsorp-
tion). Fast-forward to the present day and we now know that
these genes encode the brush border sodium−glucose
cotransporters (SGLT1 and SGLT2). Moreover, studies of
Fanconi–Bickel syndrome, a genetic disease resulting in se-
vere glucose loss in the urine [7], point to GLUT2 as the
kidney basolateral glucose transporter [8, 9]. These genetic
conditions, discussed later, have been instrumental in reveal-
ing the key players in renal glucose transport: SGLT1, SGLT2
and GLUT2.
In this review, we summarise the physiology of renal
SGLTs and GLUTs, and provide rationale for the development
of SGLT2 inhibitors to treat type 2 diabetes, as well as
outlining the limitations of this therapeutic approach [10, 11].
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Fig. 2 Glucose reabsorption by the proximal tubule. (a) Schematic rep-
resentation of a single nephron, the functional unit of the kidney. (b)
Glucose concentration (mmol/l) measured in micropuncture studies as
fluid flows from the glomerulus along the tubule [51]. SGLT2 and
GLUT2 are responsible for glucose reabsorption in the S1 and S2
segments, and SGLT1 and GLUT2 are responsible for glucose reabsorp-
tion in the S3 segment . Adapted from [6], distributed under the terms of
the CC BY 4.0 Attribution License (http://creativecommons.org/licenses/
by/4.0/). This figure is available as part of a downloadable slideset
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Fig. 1 A drawing illustrating a cross-sectional view of the human kidney,
showing the location of one of the 1 million nephrons in the kidney. The
renal vein and renal artery are shown in black and red, respectively. The
average daily filtered glucose load, urinary glucose excretion and glucose
reabsorption in healthy adults are also shown. Phlorizin (Pz) increases
glucose excretion to the filtered load and eliminates glucose reabsorption.
This figure is available as part of a downloadable slideset
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Cellular mechanisms for glucose reabsorption
The current models for glucose reabsorption from the glomerular
filtrate by SGLT2 and SGLT1 in the different segments of the
proximal tubule, S1/S2 and S3, are shown in Fig. 3. In both S1/
S2 and S3 segments, the first stage is glucose transport across the
apical membrane by SGLTs. This leads to glucose accumulation
within the epithelium, modulated to some extent by intracellular
metabolism. The glucose concentration gradient between the cell
and plasma in turn drives the second stage: net passive exit of
glucose through the basolateral membrane, towards the plasma,
via GLUT2. The basolateral Na+/K+ pump (which extrudes three
sodium ions for every two potassium ions entering the cell)
maintains the sodium gradient across the apical membrane by
pumping sodiumout of the cell, towards plasma. Inhibition of the
Na+/K+ pump by cardiac glycosides blocks the pumping of so-
dium out of the cell, with the concomitant rise in intracellular
sodium concentration. The elimination of the sodium gradient
across the apical membrane results in the loss of sodium–glucose
cotransport across the apical membrane. Thus, the two-stage pro-
cess, together with the absorption of glomerular fluid, accounts
for the complete absorption of glucose by the time the filtrate
reaches the end of the proximal tubule (Fig. 2).
Cloning renal glucose transporters
In 1987, members of the Wright laboratory began pioneering
work that resulted in the identification of SGLTs and their func-
tional properties. The rabbit intestinal transporter was first iden-
tified by expression cloning [12], followed by homology cloning
of the human intestinal SGLT1 and renal SGLT2 transporters
[13, 14]. The SGLTs belong to a human gene family, SLC5,
which contains 12 members, including sodium-coupled trans-
porters for myoinositol, fructose, iodide and short-chain fatty
acids [6, 15, 16]. SGLT2 (also known as SLC5A2) mRNA is
almost exclusively expressed in the kidney, while SGLT1
(SLC5A1) mRNA is found mainly in the small intestine and is
only expressed to a small extent in the kidney [6, 17]. A single-
cell transcriptomic study of mouse kidney has revealed that Sglt2
is a unique marker gene for cells of the S1 segment of the prox-
imal tubule [18]. Glut2 (also known as Slc2a2) is expressed in
both S1 and S3, while Sglt1 is expressed at a low level along the
proximal tubule, with a somewhat higher level in S3. The SGLT
genes code for membrane proteins with 14 transmembrane heli-
ces, as confirmed by the crystal structures of a bacterial homo-
logue, vSGLT [19, 20]. The crystal structures have also provided
important clues about the SGLT transport mechanism (detailed
below).
Location of SGLTs in the kidney The localisation of SGLT1 and
SGLT2 in the kidney has been determined by immunohisto-
chemistry using antibodies to the cloned transporters [21–25].
SGLT2 is found in the apical membrane of the S1 and S2 seg-
ments of the proximal tubule, while SGLT1 is restricted to the
apical membrane of the S3 segment. In rodents, SGLT1 is also
located in the apical membrane of the ascending limb of the loop
of Henle, but the functional significance of this finding is un-
known. We note that currently used immunocytochemical
methods do not provide quantitative information about the den-
sity or functional activity of targeted membrane proteins.
Actually, it is the number of SGLT proteins and their turnover
number that determine the functional activity of SGLTs in the cell
membrane. This information is not available for SGLT2 and
SGLT1 in the apical membrane of S1/S2 and S3 segments.
Functional properties The functional properties of SGLT1 and
SGLT2 have been determined by their expression in heterolo-
gous expression systems such as Escherichia coli, Xenopus
laevis oocytes, and cultured cells lacking endogenous activity,
e.g. human embryonic kidney cells (HEK 293) and African
green monkey kidney, SV40 transformed cells (COS-7) (see [6,
16, 26]). In these systems, the kinetics of sodium–glucose co-
transport have been determined as a function of extracellular and
intracellular sodium, sugar and phlorizin concentrations and
membrane potential. For now, it suffices to summarise that, at
an extracellular NaCl concentration of 150 mmol/l, a membrane
potential of −50 mV and at 37°C, the human SGLT2 has an
apparent affinity constant (Km) of 5 mmol/l (Km = the substrate
concentration at which the transport velocity is one-half its max-
imal value), and a sodium:glucose coupling ratio of 1:1. In con-
trast, under the same conditions, human SGLT1 has a glucose
Km of 2 mmol/l and a sodium:glucose coupling ratio of 2:1 (Fig.
3). These properties are consistent with the hypothesis that, in
humans, the bulk of glucose is absorbed in S1/S2 by SGLT2 and
GLUT2, with complete reabsorption occurring in S3, enabled by
the higher affinity of human SGLT1 for glucose and the 2:1
sodium:glucose coupling ratio.
How do we know that the current models for glucose absorp-
tion in the proximal tubules are correct? Evidence for the
importance of SGLT1, SGLT2 and GLUT2 has been obtained
using knockout mice and a non-invasive imaging method to
monitor urinary excretion, micro positron emission tomography
(microPET) [27]. Figure 4 shows the time course of excretion of
two PET tracers into the urinary bladder of mice: 2-deoxy-2-
fluoro-[18F]-D-glucose (2-FDG), which is a substrate for
GLUT2 but not for SGLTs, and methyl-4-fluoro-[18F]-4-deoxy-
D-glucopyranoside (Me-4FDG), a substrate for SGLTs with only
low affinity for GLUT2. After intravenous injection of 2-FDG,
the tracer is rapidly excreted into the urinary bladder of wild-type
mice at a rate approximating the filtered load, consistent with the
fact that 2-FDG is not a substrate for apical SGLTs. On the other
hand, there is no measurable excretion of Me-4FDG, consistent
with this tracer being a substrate for SGLTs in the apical mem-
brane and a low-affinity substrate of GLUT2 in the basolateral
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membrane. InGLUT2 knockoutmice,Me-4FDG is excreted at a
rate comparable to 2-FDG.While, in SGLT1 and SGLT2 knock-
out mice, Me-4FDG is excreted, albeit less than the filtered load.
Overall, these results are consistent with the roles of SGLT1,
SGLT2 and GLUT2 in renal glucose reabsorption.
Further evidence comes frommeasurement of 24 h glucose
excretion in SGLT1, SGLT2 and dual SGLT1/SGLT2 knock-
out mice [28]. In double knockout mice, the entire filtered
glucose load is excreted in the urine, while in single SGLT2
and SGLT1 knockout mice, 67% and 98% of the filtered glu-
cose load is reabsorbed, respectively. Some patients with trun-
cation mutations in SGLT2 have been found to excrete less
than 50% of the filtered glucose load, while those with trun-
cation mutations in SGLT1 have only mild glucosuria (see:
[29]; Table 7.1 in [30]; Table 6 in [6]). Finally, in both mice
and humans the ‘knockout’ of functional GLUT2 (truncation
mutations in GLUT2 results in massive glucosuria [9].
Collectively, this data suggests that, in both mice and men,
in the early proximal tubule (S1/S2), SGLT2 reabsorbs the
bulk of the filtered glucose load and that, in the late proximal
tubule (S3), SGLT1 provides a reserve capacity for up to 70%
of the filtered load. In all three segments (S1, S2 and S3),
GLUT2 in the basolateral membrane is essential for complet-
ing glucose absorption across the tubule.
Inhibition of glucose reabsorption
External phlorizin acts as a high-affinity, specific, non-
t ranspor ted , compet i t ive , dead-end inhib i tor of
sodium:glucose transport in and out of a cell. It contains a
glucose structure on one end, which binds to the glucose-
binding site on SGLTs, and an aglycone tail (phloretin), which
binds to the wall of the hydrophilic cavity leading to the
SGLT2
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Fig. 3 Reabsorption of glucose in the proximal tubule. (a) Epithelial cells
of the S1 and S2 segments of the proximal tubule express SGLT2 on the
apical membrane and GLUT2 on the basolateral membrane. (b) Epithelial
cells of the S3 segment express SGLT1 on the apical membrane and
GLUT2 on the basolateral membrane. In both S1/S2 and S3 segments,
glucose reabsorption occurs, first via glucose transport across the apical
membrane by SGLTs and then by passive glucose exit towards the plasma
via GLUT2. The sodium gradient across the apical membrane is main-
tained by the basolateral Na+/K+ pump. At an extracellular NaCl
concentration of 150 mmol/l, a membrane potential of −50 mV and at
37°C, the human SGLT2 has a Km for glucose of 5 mmol/l, a Ki for
phlorizin of 11 nmol/l and a sodium:glucose coupling ratio of 1:1.
Under the same conditions, human SGLT1 has a glucose Km of
2 mmol/l, a phlorizin Ki of 140 nmol/l, and a sodium:glucose coupling
ratio of 2:1. Adapted from [6], distributed under the terms of the CC BY
4.0 Attribution License (http://creativecommons.org/licenses/by/4.0/).
This figure is available as part of a downloadable slideset
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glucose-binding site (described further below). Internal
phlorizin, even at high cytoplasmic sodium concentrations,
is a poor inhibitor of both forward and reverse glucose trans-
port [31].
Several studies have been carried out to confirm and
explain the total inhibition of glucose reabsorption by
phlorizin that is reported in humans [1]. For example,
using microPET to monitor Me-4FDG excretion into the
urinary bladder, we have shown that intravenous injection
of phlorizin or the specific SGLT2 inhibitor dapagliflozin
rapidly increases excretion of Me-4FDG into the urinary
bladder (Fig. 5a) [32]. Dapagliflozin acts specifically on
the kidneys, as shown by microPET imaging of mice
injected with 4-[18F]fluoro-dapagliflozin (F-Dapa) [32].
F-Dapa binds specifically to the external surface of func-
tional SGLT2 in the plasma membrane (with a binding
constant of 4 nmol/l) [33] and is displaced by phlorizin
and cold (non-radioactive) dapagliflozin. In rodents, the
kidney is the only organ that shows significant specific F-
Dapa binding (Fig. 5b). As SGLT2 inhibitors only bind to
functional SGLT2 proteins in plasma membranes [31],
this extends the immunohistochemical finding of the
kidney-specific location of SGLT2 in rodents [23].
So, where in the kidney does F-Dapa bind? This has
been determined by ex vivo autoradiography (Fig. 5c,d).
The inhibitor binds to the outer cortex of the whole mouse
kidney and (as shown at higher magnification) only
within tubules surrounding the glomeruli. This pattern of
binding is similar to the hybridisation of Sglt2 (also
known as Slc5a2) mRNA in rat kidneys and SGLT2 anti-
body binding in mouse, rat and human kidneys. We con-
clude that dapagliflozin is filtered from the plasma by the
glomerulus and then binds to SGLT2 in the early proximal
tubule, where it inhibits glucose absorption. Biochemical
studies in dog kidney have shown that [3H]-phlorizin is
filtered by the kidney, binds to the proximal tubule brush
border membranes, and is displaced and excreted into the
urine by excess cold (non-radioactive) phlorizin [34].
Unlike phlorizin, dapagliflozin and other SGLT2 inhibi-
tors are not excreted into the urine, implying that they are
reabsorbed further down the nephron and excreted in bile
[32].
Molecular mechanisms of glucose transport
by SGLTs and GLUTs
A mechanical model of sodium–glucose cotransport by
SGLTs is shown in Fig. 6. The vast majority of informa-
tion on SGLT-mediated sodium–glucose cotransport has
come from biochemical and biophysical experiments on
human SGLT1 in heterologous expression systems, with a
more limited set of data from human SGLT2 experiments.
In addition, solving the crystal structure of the bacterial
homologue vSGLT and molecular dynamic simulations of
these structures has provided further insights into the mo-
lecular mechanisms of SGLTs. We have also learnt from
the fact that SGLTs belong to a structural family of trans-
porters that have a common five-helix inverted repeat
motif, the LeuT structural fold (see [6, 35]). Different
cotransporters and exchangers have this common structure
and so may have similar transport mechanisms. For
cotransporters and exchangers in this family, the substrate
binding sites are located in the middle of the protein, with
external and internal gates isolating the substrate from the
extracellular and intracellular solution on each side of the
membrane (Fig. 6). Having determined the structure of
GLUT transporters in the SLC2 gene family [36], it is
suggested that glucose transport through these proteins
has a similar gated mechanism to the cotransporters, but
with the difference that opening and closing of the exter-
nal and internal gates is not controlled by sodium.
SGLT1 normally couples the inward transport of two sodi-
um ions and one glucose molecule in each kinetic cycle. The
direction of the transporter is completely reversible. The rate
and direction of transport is simply a function of the extracel-
lular and intracellular sodium and glucose concentrations and
the polarity and magnitude of the membrane potential.
Cotransport of sodium and glucose by SGLT1 and SGLT2
generates an electrical current and this provides a biophysical
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Fig. 4 Urinary excretion of glucose PET tracers, 2-FDG and Me-4FDG
in wild-type, Glut2−/−, Sglt1−/− and Sglt2−/− mice. The total amount of 2-
FDG and Me-4FDG in the urinary bladder of representative mice as a
function of time after intravenous injection of radiotracer (11 MBq) is
shown. The data were fitted to a three-compartmental model for glomer-
ular filtration, reabsorption and urinary excretion, showing that the excre-
tion of 2-FDG in wild-type mice, andMe-4FDG in the Glut2−/−mice was
equivalent to the filtered glucose load. The excretion of Me-4FDG was
greater in Sglt1−/− than Sglt2−/− mice. The entire filtered load of Me-
4FDG was reabsorbed in wild-type mice. Adapted from [27] distributed
under the terms of the CC BY-NC 4.0 Attribution License (https://
creativecommons.org/licenses/by-nc/4.0/). This figure is available as
part of a downloadable slideset
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tool to measure the rate of cotransport. The sugar-activated
(inward or outward) current is observed in the presence of
sodium and is equivalent to the rate of sodium transport. In
the case of SGLT1, capacitive currents are generated by volt-
age jumps in the presence and absence of sodium, in the ab-
sence of sugar. These currents are due to the movement of
charged or polar amino acid residues of SGLT1 in the mem-
brane electric field. They have provided a powerful biophys-
ical means of measuring SGLT1 presteady state kinetics and
the number of SGLT1 proteins in the plasma membrane. As
yet, capacitive currents have not been recorded for human
SGLT2.
In the normal forward transport cycle (Fig. 6), extracellular
sodium first binds to the Na2 and Na1 sites. The Na2 site is
conserved in SGLT2 and other members of the LeuTstructural
family: in SGLT1 the residues involved in coordinating Na+
are A76, I79, S289, S392 and S293.We have evidence that the
Na1 site in human SGLT1 involves residues N78, H83, E102,
Y290 andW291 [37]. Sodium binding increases the probabil-
ity of opening the external gate so that external glucose (and
phlorizin) can bind. The residues responsible for glucose bind-
ing are N78, H83, E102, K321, Q457, Y290 and W291, and
these are conserved in human SGLT2. After binding glucose
(or phlorizin) the outer gate closes to occlude the substrate
from the external solution and then the inner gate opens to
allow glucose and sodium to escape into the cytosol. Finally,
the inner gate closes and the kinetic cycle continues to the
initial starting position. We originally proposed an ordered
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Fig. 5 (a) Time course of Me-4FDG excretion into the urinary bladder of
a rat. Me-4FDG (300 MBq) was injected intravenously into rats and
excretion into the urinary bladder measured usingmicroPET. Its excretion
into the urinary bladder (MBq) is plotted as a function of time before and
after injection of 1 mg/kg dapagliflozin (Dapa; an SGLT2 inhibitor) at
20min. Injection of dapagliflozin causes the rapid excretion ofMe-4FDG
into the urinary bladder. Similar results were obtained with intravenous
phlorizin (A. S. Yu and C. Ghezzi, unpublished results). (b) SGLT2 dis-
tribution in a rat, analysed using F-Dapa microPET. Animals were
injected with F-Dapa (300 MBq) and the distribution of the tracer was
imaged at 60 min using microPET. F-Dapa binding to organs is shown in
control conditions (white bars) or after competition with cold
dapagliflozin (black bars). Three-dimensional regions of interest (ROIs)
were drawn over each organ and the data are presented as a percentage of
the initial dose per tissue weight (%ID/g), with the exception of the
bladder, for which values are presented as percentage ID per total bladder
volume. Data are presented as the apparent density of SGLT2 in each
organ, as means + SEM. ***p ≤ 0.001 vs control. The data show that
functional SGLT2 is only expressed in the kidney. (c, d) Location of
SGLT2 in the mouse kidney, visualised using F-Dapa and ex vivo
microautoradiography and H&E staining. A mouse was injected with
148 MBq F-Dapa and after 15 min the kidney was removed and proc-
essed. (c) Aligned autoradiogram and H&E-stained image of the whole
mouse kidney. Scale bar, 1 mm. (d) F-Dapa binding to the tubules sur-
rounding a glomerulus. These images show that dapagliflozin is filtered
by glomeruli in the outer renal cortex and then binds to SGLT2 in the
early proximal tubule. Scale bar, 100 μm. Parts (b–d) are adapted with
permission of American Society of Nephrology from [32]; permission
conveyed through Copyright Clearance Center, Inc. This figure is avail-
able as part of a downloadable slideset
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internal dissociation of glucose and sodium, but recent exper-
iments and molecular dynamic studies favour the simulta-
neous release of glucose and sodium [38]. One complete cycle
takes about 20 ms.
Although kinetic studies of SGLT2 are not as advanced
as those for SGLT1, the transport model is similar (Fig.
6). A major reason for the lack of data on SGLT2 is the
low expression of this transporter in heterologous expres-
sion systems, such as X. laevis oocytes and cultured cells
at 22°C. In preliminary kinetic studies on oocytes, the
expression level of SGLT2 was less than 1% of that for
SGLT1 [39]. On learning from Ana Pajor and Chari Smith
that raising the temperature to 37°C dramatically in-
creased SGLT2 activity in cultured cells [40], we were
able to perform a robust comparison of the kinetics of
SGLT1 and SGLT2 in HEK 293 cells [26, 33]. The major
difference between SGLT2 and SGLT1 is that the
sodium:glucose coupling ratio is 1:1 for SGLT2 vs 2:1
for SGLT1 [26]. Other differences include the higher af-
finity of phlorizin to SGLT2 vs SGLT1 (Ki 11 vs
140 nmol/l), the higher affinity of gliflozins, such as
dapagliflozin to SGLT2 (Ki 4 vs 400 nmol/l), and a
narrower sugar selectivity of SGLT2 (galactose is a poor
substrate for SGLT2). Michael Coady and his colleagues
recently elucidated the reason for low SGLT2 expression
in oocytes with the discovery that co-expression of
MAP17 was required [41, 42]. Apart from small differ-
ences in kinetic variables (likely owing to the difference
in temperature of culture conditions), the kinetic
properties of SGLT2 expressed in oocytes (cultured at
22°C) were identical to those in HEK 293 cells (cultured
at 37°C). The role of MAP17 in SGLT2 expression in
oocytes is not yet understood.
Regulation of SGLTs
In HEK 293Tcells, SGLT2 is regulated over the short term by
stimulation of protein kinases, Protein kinase A (PKA) and
Protein kinase C (PKC) [43]. This reversible stimulation oc-
curs with a half-time of 10 min and is due to a change in the
maximum rate of transport. Insulin mimics the effect of PKA
and PKC activation, but this does not occur with deletion of
the only phosphorylation site on SGLT2, Ser624Ala. PKC and
PKA also regulate human SGLT1 in cultured cells, resulting
in rapid changes in the trafficking of an intracellular pool of
transporters to the cell membrane. In oocytes, biophysical and
electron microscopic studies show that PKA- and PKC-
induced increases in SGLT1 activity is due to an increase in
the number of SGLT1 proteins in the cell membrane, at a rate
of 1 × 107 molecules per second [6, 44]. There was no effect of
insulin on human SGLT1 trafficking.
Structure of SGLTs
Following the work of Eric Turk in purifying the bacterial
transporter, vSGLT [45], the x-ray structure was solved in
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gate
Outer 
vestibule
Inner
gate
Inner 
vestibule
Glucose
Na1
Na2
1 2
5 4
3
OUT
Fig. 6 A mechanical model for sodium-coupled sugar transport. Sodium
(green circle) binds first to the extracellular side (‘OUT’; state 1) to open
the outer gate (state 2), permitting the sugar (glucose; yellow hexagon) to
bind and be trapped in the bound site (state 3). The binding of both
substrates induces a conformational change to an ‘inward facing’ confor-
mation, resulting in the opening of the inner gate (state 4) and the release
of Na+ and sugar into the cell interior. After the release of both substrates,
the inner gate closes to form the inward facing ligand-free conformation
(state 5). The cycle is completed by the change in conformation to the
outward facing ligand-free (state 1). Phlorizin binds at the second point in
the process (state 2). Adapted from [6], distributed under the terms of the
CC BY 4.0 Attribution License (http://creativecommons.org/licenses/by/
4.0/). This figure is available as part of a downloadable slideset
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two conformations [19, 20]. The structures have provided
unique insights into the mechanism of sodium-coupled
sugar transport, as incorporated into the transport model
(Fig. 6). As aforementioned, the protein has 14 transmem-
brane helices with a core-inverted repeat of transmem-
brane helices 1–5 and 6–10, each containing a discontin-
uous helix (transmembrane helix [TM]1 and TM6). The
substrate binding site is in the middle of the protein, ad-
jacent to the discontinuous helices (N78, H83, E102,
K321 Q457, Y290 and W291), and occluded from the
external and internal solutions by external and internal
gates. The relatively high sequence identities and similar-
ities between vSGLT, SGLT1 and SGLT2 have made it
possible to construct homology models of the human pro-
teins (Fig. 7). In the sugar occluded state (Fig. 6, state 3)
glucose is coordinated by N78, H83, E102, K321, Q457,
Y290 and W291, and is excluded from contact with the
external solution by hydrophobic residues (L84, F98 and
F453) and the internal solution, in part, by Y290. A com-
mon Na2 sodium-binding site in the SGLT1 membrane
and other proteins within the LeuT structural family is
proposed at S393 (along with A76, I79, S389 and S392;
not shown in Fig. 6). Mutations of each of the SGLT1
sugar and sodium coordination residues dramatically alter
sugar binding, whereas mutations of the external gate
residues do not [46].
Considerable progress has been made by using the
structure of vSGLT to examine the molecular dynamics
of SGLTs (interested readers are referred to the literature,
e.g. [20, 38]). These and other biophysical studies of hu-
man SGLT1 provide insights into the conformational
changes associated with sodium binding and isomerisation
of the transporter between the outward and inward facing
structures (e.g. see [37, 47]).
Inhibitors of glucose reabsorption
The lead compound for the development of SGLT drugs was
phlorizin [48]. As indicated above, this plant glucoside is a
non-transported, specific competitive inhibitor of SGLT2 and
SGLT1, with a Ki of 11 nmol/l and 140 nmol/l, respectively. It
preferentially binds to the external surface of the SGLTs in the
presence of external sodium, blocking glucose transport (in-
ward or outward). The aglycones of phlorizin (phloretin) and
dapagliflozin are poor, non-competitive inhibitors of SGLTs,
indicating that the glycosides bind to both the glucose-binding
pocket and an adjacent lipophilic vestibule leading to the
glucose-binding site (Fig. 8). There is remarkable selectivity
in the binding of gliflozins to SGLTs; for example,
dapagliflozin binds to SGLT2 with a much greater affinity
than to SGLT1, and galacto-dapagliflozin has orders of mag-
nitude lower affinity for SGLT1 than SGLT2 [33].
Fig. 7 Homology model of the human SGLT2 based on the inward fac-
ing, occluded conformation of vSGLT (as described in [19]). Helices are
represented as tubes. For clarity, helices −1 and 11–14 have been removed
and helices 1, 2 and 10 are depicted as transparent. TM3 is coloured
orange. Highlighted are the residues forming the glucose-binding site
and the inner and outer gates EL8a and EL8b are helices in the external
loop linking TM7 and TM8. This figure is available as part of a
downloadable slideset
Fig. 8 The external vestibule of human SGLT1 in the outward facing,
sodium-bound conformation (Fig. 6, state 2). The vestibule was mapped
using fluorescent reagents covalently bound to cysteine residues in the
sugar-binding site, e.g. tetramethylrhodamine (TAMRA) bound to
Y290C. The location of transmembrane helices (TM) of the structural
model of SGLT1 are shown (some helices have been removed for clarity),
along with the boundary of the 600 Å3 vestibule (blue area) bounded by
the outer ends of TM1, TM2, TM3, TM6, TM9 and TM10. Reproduced
from [47], distributed under the terms of the Creative Commons
Attribution-NonCommerical-NoDerivatives International License 4.0
(CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
This figure is available as part of a downloadable slideset
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A mutational analysis of phlorizin binding to SGLT1
confirms that the sugar-binding site is important for both
glucose and phlorizin binding, in that there was a linear
relationship between glucose Km and phlorizin Ki [46]. A
major exception is that mutation of an outer gate residue,
F101C, increased phlorizin Ki by 200-fold with no change
in glucose Km. This indicates an interaction, possibly π–π
bonding, between F101 and the phlorizin aglycone.
Additional clues about the location of the phlorizin agly-
cone binding site comes from voltage clamp fluorometery
of SGLT1, which identified that a 600 Å3 vestibule leads to
the glucose-binding site in the sodium-bound open confor-
mation (Fig. 6, state 2, and Fig. 8) [47]. This vestibule is
lined with hydrophobic resides on TM1, TM2, TM6, TM9
and TM10 (Fig. 7). We anticipate that gliflozins bind to a
similar site in both SGLT1 and SGLT2, and this is support-
ed by molecular dynamic studies of inhibitor binding to
SGLTs [49]. The success of SGLT2 drugs is, in large part,
due to their high affinity for SGLT2 and the limited expres-
sion of this transporter in the kidney cortex (see above).
The development of GLUT2 drugs to treat diabetes has not
been practical owing to the close structural and functional
similarity between GLUT family members and the vital func-
tions of GLUTs throughout the body [36].
Inherited disorders of renal glucose
transporters
As previously mentioned, there are three known rare, autoso-
mal recessive disorders of SGLTs and GLUT2, glucose–ga-
lactose malabsorption (OMIM 182380), familial renal
glucosuria (OMIM 233100) and Fanconi–Bickel syndrome
(OMIM 227810), all of which result in mild to excessive
glucosuria (1–150 g [1.73 m]−2 day−1 [see textbox below]).
In glucose–galactose malabsorption, mutations in SGLT1
cause a defect in intestinal glucose (and galactose) absorption,
resulting in mild glucosuria (see [6, 50]). These mutations
cause malabsorption due to mistrafficking of SGLT1 to the
brush border membrane. In contrast, mutations in SGLT2
cause renal glucosuria (from 1 g [1.73 m]−2 day−1 to 150 g
[1.73 m]−2 day−1) without defects in intestinal absorption.
Only in cases of homogeneous truncation mutations in
SGLT2 is it reasonable to expect severe glucosuria, but the
reserve capacity of SGLT1 should be taken into account.
Unlike glucose–galactose malabsorption, there are no compre-
hensive studies of the transport properties of SGLT2 mutants,
largely due to the low expression of SGLT2 in heterologous
expression systems (as detailed above). This, and the incom-
plete clinical study of individuals with familial renal
Inherited disorders of SGLT1, SGLT2 and GLUT2
Familial renal glucosuria (OMIM 233100) [6, 52]
Benign, rare, autosomal recessive disorder
Presents as isolated glucosuria (1–150 g [1.73 m]
−2 
day
−1
)
Homogenous mutations in SGLT2 in 60% of patients
Mutations include missense, nonsense, frame shift, splice site and deletion mutations
Those with premature stop mutations (e.g. V347X) have severe glucosuria
Glucose–galactose malabsorption (OMIM 182380) [6, 50]
Rare autosomal recessive defect in intestinal glucose and galactose absorption 
Patients have mild renal glucosuria. Newborns (on mother’s milk) present with diarrhoea 
Homozygous and heterogeneous SGLT1 missense, nonsense, frame shift, splice site and deletion muta-
tions. 
Mutations cause defects in tracking SGLT1 from endoplasmic reticulum to brush border membrane
Therapy is to remove lactose, glucose and galactose from diet
Fanconi–Bickel syndrome (OMIM 227810) [9]
A fatal, rare autosomal recessive disorder 
Characterised by hepatomegaly and glucosuria ranging from 40–150 g [1.73 m]
−2
 day
−1
Missense, nonsense, frame shift and splice site mutations in GLUT2
Those with truncation mutations have severe glucosuria
OMIM, Online Mendelian Inheritance in Man (www.omim.org)
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glucosuria, has led to confusion about the inheritance of this
disease. However, we expect familial renal glucosuria to be a
simple autosomal recessive disease.
Aswith SGLT2, truncationmutations ofGLUT2 are expected
to cause complete excretion of the filtered glucose load if
GLUT2 is the major glucose transporter on the proximal tubule
basolateral membrane. However, the phenotype of Fanconi–
Bickel syndrome is complex owing to the importance of
GLUT2 in the liver and other organs.
Overall, these genetic disorders, caused by mutations in
SGLT1, SGLT2 and GLUT2, support animal studies and con-
firm the importance of the three affected proteins in
reabsorbing the filtered glucose load in healthy humans.
Summary
Thirty years ago, the cloning of human SGLT1, SGLT2 and
GLUT2 was a major breakthrough in the identification of trans-
porters involved in renal glucose absorption. Subsequent ad-
vances in molecular biology permitted the development of ge-
netic mouse models lacking SGLT1, SGLT2 and GLUT2, fur-
thering our understanding of the role of these transporters in the
proximal tubule. Based on the assumption that SGLT2 was re-
sponsible for the bulk of glucose reabsorption, the pharmaceuti-
cal industry in Japan, USA and Europe invented SGLT2 inhibi-
tors to treat type 2 diabetes. Although these drugs do lower blood
glucose levels in patients with diabetes without causing
hypoglycaemia, they are only capable of a 50% inhibition of
glucose reabsorption and are, thus, not so effective as a mono-
therapy. In retrospect, given the huge reserve capacity of SGLT1
in the late proximal tubule, one can argue that dual SGLT2 and
SGLT1 drugs may be more effective in controlling renal glucose
excretion.
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